Trial Profile
A Randomised, Double-blind, Placebo-controlled, Parallel Group, 8-week Treatment Study to Investigate the Safety, Pharmacodynamics, and Effect of the TLR7 Agonist, GSK2245035, on the Allergen-induced Asthmatic Response in Subjects With Mild Allergic Asthma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs GSK 2245035 (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 06 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database
- 10 May 2018 Status changed from active, no longer recruiting to completed.
- 10 May 2018 This trial has been completed in Germany , according to European Clinical Trials Database